1.Date of occurrence of the event:2024/12/18

2.Company name:TOP PHARM.MEDICALWARE COMPANY LIMITED.and TOP Biological Technology Company Limited.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries

4.Reciprocal shareholding ratios:51%

5.Cause of occurrence:This notification is hereby given in accordance with Article 319 and 73(2) of the Company Act, and Article 23(1) of the Business Merger and Acquisition Act.

6.Countermeasures:Notices and announcements to each creditor.

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1) This notification is hereby given in accordance with Article 319 and 73(2) of the Company Act, and Article 23(1) of the Business Merger and Acquisition Act.
(2) The merger of TOP Biological Technology Company Limited and TOP PHARM.MEDICALWARE COMPANY LIMITED was approved and resolved by the board of directors’meeting on 2024/11/15,and the shareholders' meeting of on 2024/12/18,respectively.which is scheduled to be effective on 2025/1/1,TOP PHARM.MEDICALWARE COMPANY LIMITED shall be the surviving company, and TOP Biological Technology Company Limited shall be the dissolved company. All rights and obligations of TOP Biological Technology Company Limited shall be assumed by TOP PHARM.MEDICALWARE COMPANY LIMITED upon the merger effective date.
(3) You may file an objection in writing with the documentary evidence of creditor's rights by a written objection from 2024/12/18, to 2025/1/17. If you fail to exercise the aforesaid rights within the prescribed time limit, you will be deemed not to demur to the merger.